Death after hematopoietic stem cell transplantation

Standard

Death after hematopoietic stem cell transplantation : changes over calendar year time, infections and associated factors. / Infectious Diseases Working Party EBMT.

in: BONE MARROW TRANSPL, Jahrgang 55, Nr. 1, 01.2020, S. 126-136.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsätzeForschungBegutachtung

Harvard

APA

Vancouver

Bibtex

@article{3a2a3cff2312454398cfc1304e590956,
title = "Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors",
abstract = "Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55'668 deaths in 114'491 patients with HSCT (83.7{\%} allogeneic) for leukemia were investigated in a landmark analysis for causes of death at day 30 (very early), day 100 (early), at 1 year (intermediate) and at 5 years (late). Mortality from all causes decreased from cohort 1 (1980-2001) to cohort 2 (2002-2015) in all post-transplant phases after autologous HSCT. After allogeneic HSCT, mortality from infections, GVHD, and toxicity decreased up to 1 year, increased at 5 years; deaths from relapse increased in all post-transplant phases. Infections of unknown origin were the main cause of infectious deaths. Lethal bacterial and fungal infections decreased from cohort 1 to cohort 2, not unknown or mixed infections. Infectious deaths were associated with patient-, disease-, donor type, stem cell source, center, and country- related factors. Their impact varied over the post-transplant phases. Transplant centres have successfully managed to reduce death after HSCT in the early and intermediate post-transplant phases, and have identified risk factors. Late post-transplant care could be improved by focus on groups at risk and better identification of infections of {"}unknown origin{"}.",
author = "Jan Styczyński and Gloria Tridello and Linda Koster and Simona Iacobelli and {van Biezen}, Anja and {van der Werf}, Steffie and Małgorzata Mikulska and Lidia Gil and Catherine Cordonnier and Per Ljungman and Diana Averbuch and Simone Cesaro and {de la Camara}, Rafael and Helen Baldomero and Peter Bader and Grzegorz Basak and Chiara Bonini and Rafael Duarte and Carlo Dufour and Jurgen Kuball and Arjan Lankester and Silvia Montoto and Arnon Nagler and Snowden, {John A} and Nicolaus Kr{\"o}ger and Mohamad Mohty and Alois Gratwohl and {Infectious Diseases Working Party EBMT}",
year = "2020",
month = "1",
doi = "10.1038/s41409-019-0624-z",
language = "English",
volume = "55",
pages = "126--136",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Death after hematopoietic stem cell transplantation

T2 - changes over calendar year time, infections and associated factors

AU - Styczyński, Jan

AU - Tridello, Gloria

AU - Koster, Linda

AU - Iacobelli, Simona

AU - van Biezen, Anja

AU - van der Werf, Steffie

AU - Mikulska, Małgorzata

AU - Gil, Lidia

AU - Cordonnier, Catherine

AU - Ljungman, Per

AU - Averbuch, Diana

AU - Cesaro, Simone

AU - de la Camara, Rafael

AU - Baldomero, Helen

AU - Bader, Peter

AU - Basak, Grzegorz

AU - Bonini, Chiara

AU - Duarte, Rafael

AU - Dufour, Carlo

AU - Kuball, Jurgen

AU - Lankester, Arjan

AU - Montoto, Silvia

AU - Nagler, Arnon

AU - Snowden, John A

AU - Kröger, Nicolaus

AU - Mohty, Mohamad

AU - Gratwohl, Alois

AU - Infectious Diseases Working Party EBMT

PY - 2020/1

Y1 - 2020/1

N2 - Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55'668 deaths in 114'491 patients with HSCT (83.7% allogeneic) for leukemia were investigated in a landmark analysis for causes of death at day 30 (very early), day 100 (early), at 1 year (intermediate) and at 5 years (late). Mortality from all causes decreased from cohort 1 (1980-2001) to cohort 2 (2002-2015) in all post-transplant phases after autologous HSCT. After allogeneic HSCT, mortality from infections, GVHD, and toxicity decreased up to 1 year, increased at 5 years; deaths from relapse increased in all post-transplant phases. Infections of unknown origin were the main cause of infectious deaths. Lethal bacterial and fungal infections decreased from cohort 1 to cohort 2, not unknown or mixed infections. Infectious deaths were associated with patient-, disease-, donor type, stem cell source, center, and country- related factors. Their impact varied over the post-transplant phases. Transplant centres have successfully managed to reduce death after HSCT in the early and intermediate post-transplant phases, and have identified risk factors. Late post-transplant care could be improved by focus on groups at risk and better identification of infections of "unknown origin".

AB - Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55'668 deaths in 114'491 patients with HSCT (83.7% allogeneic) for leukemia were investigated in a landmark analysis for causes of death at day 30 (very early), day 100 (early), at 1 year (intermediate) and at 5 years (late). Mortality from all causes decreased from cohort 1 (1980-2001) to cohort 2 (2002-2015) in all post-transplant phases after autologous HSCT. After allogeneic HSCT, mortality from infections, GVHD, and toxicity decreased up to 1 year, increased at 5 years; deaths from relapse increased in all post-transplant phases. Infections of unknown origin were the main cause of infectious deaths. Lethal bacterial and fungal infections decreased from cohort 1 to cohort 2, not unknown or mixed infections. Infectious deaths were associated with patient-, disease-, donor type, stem cell source, center, and country- related factors. Their impact varied over the post-transplant phases. Transplant centres have successfully managed to reduce death after HSCT in the early and intermediate post-transplant phases, and have identified risk factors. Late post-transplant care could be improved by focus on groups at risk and better identification of infections of "unknown origin".

U2 - 10.1038/s41409-019-0624-z

DO - 10.1038/s41409-019-0624-z

M3 - SCORING: Journal articles

C2 - 31455899

VL - 55

SP - 126

EP - 136

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 1

ER -